The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial

药物协调工具安全消息传递 (SMMRT) 试用

基本信息

  • 批准号:
    10176578
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Medication discrepancies, defined as unintentional differences found between patients' medical records and patients' reports of the medication they are taking, occur frequently after hospital discharge, predisposing to adverse drug events (ADEs), emergency department visits and readmissions. Resolving medication discrepancies - medication reconciliation - is mandated at every care transition, but little is known about intervention strategies to improve medication reconciliation in the post-discharge period, when patients may lack prompt access to primary care and are at high risk for ADEs. To address this gap, we developed and pilot tested the Secure Messaging for Medication Reconciliation Tool (SMMRT), with a pharmacist communicating with Veterans to review medications and reconcile discrepancies after hospital discharge via Secure Messaging (SM), within My HealtheVet (MHV), VA's patient portal. Our pilot study detected, on average, two clinically important medication discrepancies per Veteran immediately following discharge and demonstrated that Veterans could interact with the pharmacist asynchronously to resolve discrepancies. Veterans found SMMRT easy to use and indicated they would willingly use it again. We therefore propose the SMMRT Trial, in which we will optimize the end-users' experience with SMMRT, conduct a randomized controlled trial (RCT) of MHV training and SMMRT to reduce hospital utilization, and evaluate SMMRT for potential future implementation. For Aim 1, we will conduct formal usability assessment of SMMRT among Veterans (N=10) pharmacists (N=10) and nurses (N=10), refining the user interface for optimal acceptability and effectiveness. For Aim 2, we will mount a 3-arm RCT to evaluate the effects of MHV training and SMMRT, randomizing 1,400 hospitalized Veterans to compare 1) Usual Care (UC), 2) UC + MHV enrollment and training (i.e., "MHV training"), and 3) UC + MHV training + SMMRT after discharge. The primary outcome measure will be 30-day hospital utilization (combined readmissions plus emergency department visits) with the primary hypothesis that SMMRT will reduce hospital utilization compared with UC. For Aim 3, we will carry out a formative evaluation of the interventions for potential future implementation, with qualitative analysis of in-depth interviews from among 20 Veterans and 10-15 primary care nurses. We will collaborate with operational partners: the Veterans' Consumer Health Information Office, which oversees MHV program activities, and the National Medication Reconciliation Initiative, within Pharmacy Benefits Management, responsible for implementing the VA Directive regarding medication reconciliation. If proven effective, SMMRT will have several impacts on Veterans and their health care: 1) decreased medication discrepancies; 2) decreased emergency room visits and hospital readmissions following discharge, which are commonly the result of ADE; 3) improved measures of patient- engagement, patient-centeredness, and patient satisfaction. This study directly supports VA's Transformational Initiative to employ state-of-the-art information technology in the delivery of Veterans' health care.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amy Linsky其他文献

Amy Linsky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amy Linsky', 18)}}的其他基金

Impact of COVID-19 on implementation and outcomes of VA's Life-Sustaining TreatmentDecisions Initiative
COVID-19 对 VA 生命维持治疗决策计划的实施和结果的影响
  • 批准号:
    10417471
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Engaging Patients to Promote Deprescribing
让患者参与促进取消处方
  • 批准号:
    10359059
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Engaging Patients to Promote Deprescribing
让患者参与促进取消处方
  • 批准号:
    10607989
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
药物协调工具安全消息传递 (SMMRT) 试用
  • 批准号:
    10027247
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial
药物协调工具安全消息传递 (SMMRT) 试用
  • 批准号:
    10179472
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Patient and provider perceptions of intentional medication discontinuation
患者和提供者对有意停药的看法
  • 批准号:
    9768231
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Artificial intelligence-based health IT tools to optimize critical care pharmacist resources through adverse drug event prediction
基于人工智能的健康 IT 工具,通过药物不良事件预测来优化重症监护药剂师资源
  • 批准号:
    10503268
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases
普拉格雷和氯吡格雷出血风险的比较:使用药物不良事件报告数据库的回顾性研究
  • 批准号:
    18K14954
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Adverse Reactions to Potent Opioids: An analysis using the largescale Japanese Adverse Drug Event Report database
对强效阿片类药物的不良反应:使用大型日本药物不良事件报告数据库进行的分析
  • 批准号:
    15K08111
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Implementation and Evaluation of an Enhanced PharmaNet-Based Adverse Drug Event Reporting Platform to Improve Patient Safety and Meet Adverse Drug Reaction Reporting Requirements
基于 PharmaNet 的增强型药品不良事件报告平台的实施和评估,以提高患者安全并满足药品不良反应报告要求
  • 批准号:
    334597
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
  • 批准号:
    9123554
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
EMR Adverse Drug Event Detection for Pharmacovigilance
用于药物警戒的 EMR 药物不良事件检测
  • 批准号:
    8772667
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Integration of spatial epidemiology and pharmacoepidemiology for the practical use of the adverse drug event report database with related applications
空间流行病学和药物流行病学的整合,用于药物不良事件报告数据库的实际使用及相关应用
  • 批准号:
    26540012
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Epidemiology of Adverse Drug Event in intensive care unit (ICU) and neonatal ICU (NICU)
重症监护病房(ICU)和新生儿重症监护病房(NICU)药品不良事件流行病学
  • 批准号:
    25860484
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Optimizing Adverse Drug Event Reporting within a Provincial Medication Information System to Improve Pharmacovigilence and Inform Pharmaceutical Policy
优化省级药品信息系统内的药品不良事件报告,以提高药物警戒并为药品政策提供信息
  • 批准号:
    284162
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
    Fellowship Programs
Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy
PharmaNet 中的药物不良事件报告可提高患者安全并为政策提供信息
  • 批准号:
    273419
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了